ZYBERNO
Stock Report
Updated Sep 1, 2026

Bolt Biotherapeutics, Inc. (BOLT)

Healthcare • NASDAQ

$4.02

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
Bolt Biotherapeutics, Inc. (BOLT) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-126.2%)
Debt-to-Equity (Solvency Risk):CRITICAL (3.42x)
Operating Margin (Operational Efficiency):CRITICAL (-654.5%)
Return on Capital (Capital Efficiency):CRITICAL (-107.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Bolt Biotherapeutics, Inc. (BOLT) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, BOLT generated -$61.33M in Owner Earnings. Capital was deployed as follows: $41.00K invested in capital expenditures. Reinvestment rate: 5.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.02
Market Cap:$6.80M

Valuation Multiples (3)

P/B Ratio:0.54x
P/S Ratio:1.45x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$15.56M

Price Action & Momentum (3)

Momentum Percentile:15 / 100
% of 52-Week High:55.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-54.7%
Reinvestment Rate:5.3%
Fundamental Growth Rate (g):-5.7%

Margin Analysis (3)

Operating Margin Ttm:-654.5%
Net Margin Ttm:-611.5%
Ebitda Margin:-621.4%

TTM Performance (2)

Operating Margin Ttm:-654.5%
Net Margin Ttm:-611.5%

Yield Metrics (2)

Earnings Yield:-$656.12
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:20.2%
Latest Earnings Filed:2026-08-11

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.61x
Quick Ratio:2.61x
Cash Ratio:1.63x

Leverage Analysis (3)

Debt To Equity Ttm:3.42x
Debt-to-Equity Ratio:3.42x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:12,697,000.00
Cash And Cash Equivalents:12,860,000.00
Long Term Debt:$18.53M
Net Debt:$8.76M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $4.70M
Linear Growth: -50.0%
📊 Click to view full BOLT Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$30.76M

Bottom Line Performance (3)

-$28.74M
Income Before Tax:-$33.38M
Ebitda Ttm:-29,207,000.00

Operating Expenses (5)

Operating Expenses:35,463,000.00
R And D Expense:21,501,000.00
Sga Expense:11,674,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:430,020.0%
Sga To Revenue Percentage:233,480.0%
Ebitda Margin:-621.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$40.34M
Current Assets:$20.56M
Ppe Net:4,185,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:27,704,000.00
Current Liabilities:7,867,000.00
Long Term Debt:$18.53M
Short Term Debt:$3.09M

Equity & Capital (3)

Equity:$12.64M
Retained Earnings:-$475.74M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:868,000.00

Special Items (2)

Contract Liabilities:819,000.00
Stock Based Compensation:552,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$34.51M-$34.55M

Investment Activities (2)

Investing Cash Flow:$7.92M
Capital Expenditures Ttm:41,000.00

Financing Activities (3)

Financing Cash Flow:$6.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:6,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,556,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-21.98
-$21.98
Earnings Per Share Ttm:-$17.00

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.78
Operating Cash Flow Per Share:-$23.57

Book Value & Capital (2)

Book Value Per Share:$7.48
Cash Per Share:7.61

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.09x
Working Capital Turnover Ttm:0.37x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:67.41
Cash Conversion Cycle:-2,065.41
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$61.33M

Damodaran Growth Analysis (2)

Reinvestment Rate:5.3%
Fundamental Growth Rate (g):-5.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-47.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:BOLT
Company Name:Bolt Biotherapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.69M
Shares Outstanding Basic:1.69M
Shares Outstanding Diluted:1.69M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 16:14:42 UTC
Data Timestamp:2026-08-21T19:19:18.495593
Scroll to Top